UW-Madison researchers have isolated and characterized a BA.2 strain of the Omicron variant of SARS-CoV-2.
Learn More

UW-Madison researchers have isolated and characterized a BA.1 strain of the Omicron variant of SARS-CoV-2.
Learn More

The present invention from UW Madison researchers provides compositions and methods of treating prostate cancer using a combination of a DNA vaccine, PD-1 inhibitor and an IDO inhibitor. Further, meth...
Learn More

UW – Madison researchers have determined that SARS-CoV-2 infection induces antibodies against both structural and non-structural proteins and they identified epitopes in the SARS-CoV-2 membrane ...
Learn More

The present invention provides both QuilA-loaded chitosan (QAC)-encapsulated DNA vaccine compositions and viral vaccine compositions that encode a SARs-CoV-2 spike (S) protein, a SARs-CoV-2 nucleocaps...
Learn More

The invention provides a vaccine comprising a recombinant biologically contained filovirus and methods of making and using those viruses.
Learn More

The global food industry continues to search for sustainable fish protein sources. Increasingly, tilapia and other fish species have become the focus of healthy and sustainable farming methods. Howeve...
Learn More

Ebola Virus Disease (EVD) is a severe and highly fatal hemorrhagic fever that affects humans and other mammals. It is caused by the Ebola virus, a single-stranded RNA virus that encodes seven structur...
Learn More

Most influenza vaccines are produced in embryonated chicken eggs, but increasingly influenza vaccines are produced in other systems. MDCK (Madin-Darby Canine Kidney) cells are one of two mammalian cel...
Learn More

Provided herein are antigenic peptides comprising the SARS-CoV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, non­toxic tetanus toxin varia...
Learn More

The present disclosure relates to vims-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial vims (RSV) infection. Specifically, the disclosure provides vi...
Learn More

A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well th...
Learn More

The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isola...
Learn More

The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isola...
Learn More

A vector, composition and method to improve influenza virus replication by inhibiting miRNA lec-7C binding to influenza virus mRNA and/or cRNA.
Learn More

Compositions and methods to prepare influenza virus-like particles (VLPs) are provided.
Learn More

The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant ...
Learn More

Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus...
Learn More

Methods of preparing influenza viruses having altered immunodominant epitopes in HA, e.g., having one or more residues in one or more of antigenic sites A-E in HA altered, and viral vectors, e.g., inf...
Learn More

A mammalian or avian cell line that expresses high levels of human influenza virus receptors is provided. In one embodiment, the cell line supports human influenza virus, e.g., human A/H3 influenza vi...
Learn More

Quil-A chitosan spherical nanostructure complexes as well as methods of making and using such complexes are disclosed herein. Also provided are Quil-A chitosan spherical nanostrucutres loaded with one...
Learn More

Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus ...
Learn More

An isolated recombinant influenza virus is provided having PA, PB1, PB2, NP, NS, M, NA and HA viral segments, wherein the PB1 viral segment encodes a PB1 with a residue other than isoleucine at positi...
Learn More

Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more ...
Learn More

The disclosure provides for an isolated recombinant influenza virus having at least one of: a PB2 viral segment encoding PB2 with residue at position 540 that is not asparagine or a residue at positio...
Learn More